JMA Journal

Figure 1. Patient flow diagram. SOFA, Sequential Organ Failure Assessment.

Figure 2. Frequency of measurement of hemostasis markers in overall sepsis patients. (A) Frequency of measurement on admission day. (B) Frequency of measurement over time during the first 7 days after admission. PLT, platelet count; PT, prothrombin time; aPTT, activated partial thromboplastin time; Fbg, fibrinogen; FDP, fibrin degradation products; AT, antithrombin; TAT, thrombin-antithrombin complex; SF, soluble fibrin; F1+2, prothrombin fragment 1 + 2; PIC, plasmin-α2 plasmin inhibitor complex.

Figure 3. Measurement disparities according to patient status. (A) Frequency of measurement of hemostasis markers by thrombocytopenic status on admission. (B) Frequency of measurement of hemostasis markers by requirement of ICU admission. Significance was determined by Pearson’s chi-squared test. PLT, platelet count; PT, prothrombin time; aPTT, activated partial thromboplastin time; Fbg, fibrinogen; FDP, fibrin degradation products; AT, antithrombin; TAT, thrombin-antithrombin complex; SF, soluble fibrin; F1+2, prothrombin fragment 1 + 2; PIC, plasmin-α2 plasmin inhibitor complex; ICU, intensive care unit.

Figure 4. Measurement disparities according to hospital category and geographical location. (A) Frequency of measurement of hemostasis markers by category of tertiary hospital or not. Significance was determined by Pearson’s chi-squared test. (B) Heatmap showing the frequency of measurement of hemostasis markers by prefectures in Japan. PLT, platelet count; PT, prothrombin time; aPTT, activated partial thromboplastin time; Fbg, fibrinogen; FDP, fibrin degradation products; AT, antithrombin; TAT, thrombin-antithrombin complex; SF, soluble fibrin; F1+2, prothrombin fragment 1 + 2; PIC, plasmin-α2 plasmin inhibitor complex.